Interim results of a phase II study of fluorouracil (FU), leucovorin (LV), and nanoliposomal irinotecan (nal-IRI) in previously treated advanced biliary tract cancer (NAPOLI-2)

被引：0
|
作者：
Weinberg, B. [1 ]
He, A. [1 ]
Tan, B. [2 ]
Turk, A. [3 ]
Noel, M. [1 ]
Marshall, J. [1 ]
Sung, M. [4 ]
Wang, H. [1 ]
Ferguson, C. [1 ]
Swanson, N. [1 ]
Pedersen, K. [2 ]
机构：
[1] Georgetown Univ, Ruesch Ctr Cure Gastrointestinal Canc, Lombardi Comprehens Canc Ctr, Washington, DC USA
[2] Washington Univ, Sch Med, St Louis, MO USA
[3] Indiana Univ Sch Med, Dept Hematol Oncol, Indianapolis, IN USA
[4] Tisch Canc Inst Mt Sinai, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.04.287
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-231
引用
收藏
页码：S97 / S98
页数：2
相关论文
共 50 条
  • [11] Expanded analyses of NAPOLI-1: Phase 3 study of nal-IRI (MM-398), with or without 5-fluorouracil (5FU) and leucovorin (LV), versus 5-fluorouracil and leucovorin (5FU/LV), in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
    Siveke, J. T.
    Chen, L-T
    Von Hoff, D. D.
    Li, C-P
    Wang-Gillam, A.
    Bodoky, G.
    Dean, A.
    Shan, Y-S
    Jameson, G.
    Macarulla, T.
    Lee, K-H
    Cunningham, D.
    Blanc, J-F
    Hubner, R. A.
    Chiu, C-F
    Schwartsmann, G.
    Braiteh, F.
    Moyo, V.
    Belanger, B.
    Bayever, E.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 170 - 170
  • [12] A phase 1/2, open -label, dose -expansion study of liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer
    Wainberg, Z.
    Boland, P.
    Lieu, C.
    Dayyani, F.
    Macarulla, T.
    Zhang, B.
    Belanger, B.
    Moore, Y.
    Wang, T.
    Maxwell, F.
    Dean, A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [13] Impact of dose reduction or dose delay on the efficacy of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV): Survival analysis from NAPOLI-1
    Chen, L-T.
    Macarulla, T. M.
    Blanc, J.
    Mirakhur, B.
    de Jong, F. A.
    Belanger, B.
    Bekaii-Saab, T.
    Siveke, J.
    ANNALS OF ONCOLOGY, 2018, 29 : 250 - U388
  • [14] Liposomal irinotecan (nal-IRI) in combination with fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic biliary tract cancer (BTC) after progression on gemcitabine plus cisplatin (GemCis): Multicenter comparative randomized phase 2b study (NIFTY).
    Yoo, Changhoon
    Kim, Kyu-Pyo
    Kim, Ilhwan
    Kang, Myoung Joo
    Cheon, Jaekyung
    Kang, Byung Woog
    Ryu, Hyewon
    Jeong, Jae Ho
    Lee, Ji Sung
    Kim, Kyung Won
    Ryoo, Baek-Yeol
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [15] Safety across subgroups in NAPOLI-1: a phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
    Chen, L. -T.
    Siveke, J.
    Wang-Gillam, A.
    Hubner, R.
    Pant, S.
    Dragovich, T.
    Chung, V.
    Chang, D.
    Ross, P.
    Cooray, P.
    Tebbutt, N.
    Franke, F.
    Belanger, B.
    Dhindsa, N.
    de Jong, F.
    Mamlouk, K.
    Von Hoff, D.
    ANNALS OF ONCOLOGY, 2016, 27 : 110 - 110
  • [16] Efficacy and safety of liposomal irinotecan (nal-IRI) plus fluorouracil (5-FU) and leucovorin (LV) versus 5-FU/LV alone for advanced biliary tract cancer (BTC) after progression on gemcitabine-based therapy: A pooled analysis of the NIFTY and NALIRICC trials
    Yoo, C.
    Saborowski, A.
    Hyung, J.
    Wenzel, P.
    Kim, I.
    Wege, H.
    Kim, K-P
    Folprecht, G.
    Ryoo, B-Y
    Schuett, P.
    Cheon, J.
    Goetze, T. O.
    Ryu, H.
    Lee, J. S.
    Vogel, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S235 - S235
  • [17] Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer: Final results of the NIFE-trial (AIO-YMO HEP-0315), a randomized phase II study of the AIO biliary tract cancer group
    Perkhofer, L.
    Striefler, J. K.
    Sinn, M.
    Opitz, B.
    Goetze, T. O.
    Gallmeier, E.
    von Weikersthal, L. Fischer
    Jacobasch, L.
    Waldschmidt, D.
    Niedermeier, M.
    Sohm, M.
    Sookthai, D.
    Berger, A.
    Beutel, A.
    Seufferlein, T.
    Ettrich, T. J.
    ANNALS OF ONCOLOGY, 2021, 32 : S1282 - S1282
  • [18] Effects of nanoliposomal irinotecan (nal-IRI; MM-398) ± 5-fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy: results from the phase 3 NAPOLI-1 study
    Melisi, D.
    Melisi, D.
    Siveke, J. T.
    Blanc, J.
    Von Hoff, D. D.
    Wang-Gillam, A.
    Chen, L.
    Becker, C.
    Mamlouk, K.
    De Jong, F.
    Hubner, R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [19] Effects of nanoliposomal irinotecan (nal-IRI;MM-398) ± 5-Fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in NAPOLI-1: a phase 3 study in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy
    Siveke, J. T.
    Cubillo, A.
    Blanc, J. -F
    Melisi, D.
    Von Hoff, D. D.
    Wang-Gillam, A.
    Chen, L. -T
    Becker, C.
    Mamlouk, K.
    Belanger, B.
    Yang, Y.
    de Jong, F.
    Hubner, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 259 - 259
  • [20] Nomogram for predicting overall survival (OS) in patients (pts) treated with liposomal irinotecan (nal-IRI) ± 5-fluorouracil/leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy in NAPOLI-1
    Wang-Gillam, Andrea
    Hubner, Richard
    Mirakhur, Beloo
    de Jong, Floris A.
    Belanger, Bruce
    Chen, Li-Tzong
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
12345